Dementia with Lewy bodies (DLB) is a neurodegenerative disorder characterised by Parkinsonism and cognitive impairment but may also manifest multiple symptoms of dysautonomia, rapid eye movement (REM) sleep behaviour disorders, hallucinations, and cognitive fluctuations. Tomislav Babic, Vice President of the Neuroscience Franchise, and Henry J. Riordan, Executive Vice President of Medical and Scientific Affairs and Global Lead for Neuroscience at Worldwide Clinical Trials, review the current literature on DLB controlled clinical trials and suggest optimal inclusion criteria, study parameters and outcome measures to help improve the design of DLB studies and ultimately increase signal detection.
https://www.jforcs.com/7/wp-content/uploads/2016/01/Optimizing….pdf